Grassman Catherine 4
4 · HESKA CORP · Filed Jun 14, 2023
Insider Transaction Report
Form 4
HESKA CORPHSKA
Grassman Catherine
VP, CAO & Controller
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2023-06-13−35,000→ 0 totalExercise: $60.94Exp: 2030-04-15→ Common Stock (35,000 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2023-06-13−1,640→ 0 totalExercise: $60.94Exp: 2030-04-15→ Common Stock (1,640 underlying) - Award
Common Stock
2023-06-13+38,096→ 52,357 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2023-06-13−701→ 0 totalExercise: $69.77Exp: 2028-03-06→ Common Stock (701 underlying) - Award
Common Stock
2023-06-13+4,327→ 56,684 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2023-06-13−8,360→ 0 totalExercise: $60.94Exp: 2030-04-15→ Common Stock (8,360 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2023-06-13−4,299→ 0 totalExercise: $69.77Exp: 2028-03-06→ Common Stock (4,299 underlying) - Disposition to Issuer
Common Stock
2023-06-13$120.00/sh−56,684$6,802,080→ 0 total - Award
Non-Qualified Stock Option (right to buy)
2022-02-28+11,250→ 11,250 totalExercise: $60.94From: 2022-02-28Exp: 2030-04-15→ Common Stock (11,250 underlying) - Award
Non-Qualified Stock Option (right to buy)
2023-06-13+23,750→ 35,000 totalExercise: $60.94From: 2023-06-13Exp: 2030-04-15→ Common Stock (23,750 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2023-06-13−10,000→ 0 totalExercise: $70.10Exp: 2029-05-31→ Common Stock (10,000 underlying)
Footnotes (9)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, these shares of performance-based restricted stock of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
- [F2]Pursuant to the Merger Agreement, these performance-based restricted stock units were fully accelerated assuming target level of performance immediately prior to the effectiveness of the merger.
- [F3]Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $120.00 per share of common stock of the Issuer (the "Merger Consideration") on the effective date of the merger.
- [F4]Stock options of the Issuer became vested and exercisable upon achieving performance vesting conditions on February 28, 2022.
- [F5]Pursuant to the Merger Agreement, these stock options of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
- [F6]Stock options of the Issuer were canceled in the merger in exchange for an amount in cash equal to the difference, if any, between the Merger Consideration and the exercise price of such stock options.
- [F7]These stock options of the Issuer vested in two equal installments on December 31, 2021 and on December 31, 2022.
- [F8]These stock options of the Issuer vested as to two-thirds on June 1, 2020 and one-third on March 7, 2021.
- [F9]These stock options of the Issuer vested in three approximately equal annual installments beginning on March 7, 2019 and ending on March 7, 2021.